Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
PHILADELPHIA, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (NASDAQ:ONCE) announced today that Lota Zoth, CPA, a long-time financial executive at multiple publicly listed companies, has been named to the company’s Board of Directors.
Ms. Zoth has served in senior financial roles in a variety of commercial-stage companies over a 30-year career, including serving as Chief Financial Officer for MedImmune before its acquisition by AstraZeneca in 2007, and leadership experience at PSINet, Sodexho, Marriott International and PepsiCo, Inc. She began her career as an auditor with Ernst & Young, LLP. She has served as a member of multiple public and private company boards over the past decade in the biopharmaceutical industry.
"As we advance toward becoming a commercial-stage company we will benefit enormously from the addition of Lota’s experience and perspective to our Board,” said Jeffrey D. Marrazzo, co-founder and chief executive officer of Spark. “Lota has a long track record of helping emerging and commercial-stage companies support sustainable growth and innovation through financings, acquisitions, strategic planning, and day-to-day operations.”
“With a recently completed successful pivotal trial in its lead indication and progress throughout the pipeline, Spark is in a strong position to lead the field of gene therapy for many years to come,” Ms. Zoth said. “I look forward to contributing my expertise and perspective to the Board during this next exciting phase of the company’s growth.”
About Spark Therapeutics
Spark is a gene therapy leader seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s initial focus is on treating rare diseases where no, or only palliative, therapies exist. Spark’s most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, recently reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark’s validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Spark builds on two decades of research, development and manufacturing at The Children’s Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of administration. To learn more, please visit www.sparktx.com.
Investor Relations Spark Therapeutics, Inc. Stephen W. Webster Chief Financial Officer (855) SPARKTX (1-855-772-7589) Media Ten Bridge Communications Dan Quinn (781) 475-7974 [email protected]
